Postauthorization safety study of betaine anhydrous


Por: Mütze U, Gleich F, Garbade SF, Plisson C, Aldámiz-Echevarría L, Arrieta F, Ballhausen D, Zielonka M, Ramadža DP, Baumgartner MR, Cano A, Jiménez MCG, Dionisi-Vici C, Ješina P, Blom HJ, Couce ML, Meavilla-Olivas SM, Mention K, Mochel F, Morris AAM, Mundy H, Redonnet-Vernhet I, Santra S, Schiff M, Servais A, Vitoria I, Huemer M, Kožich V and Kölker S

Publicada: 1 jul 2022 Ahead of Print: 1 abr 2022
Resumen:
Patient registries for rare diseases enable systematic data collection and can also be used to facilitate postauthorization safety studies (PASS) for orphan drugs. This study evaluates the PASS for betaine anhydrous (Cystadane), conducted as public private partnership (PPP) between the European network and registry for homocystinurias and methylation defects and the marketing authorization holder (MAH). Data were prospectively collected, 2013-2016, in a noninterventional, international, multicenter, registry study. Putative adverse and severe adverse events were reported to the MAH's pharmacovigilance. In total, 130 individuals with vitamin B-6 nonresponsive (N = 54) and partially responsive (N = 7) cystathionine beta-synthase (CBS) deficiency, as well as 5,10-methylenetetrahydrofolate reductase (MTHFR; N = 21) deficiency and cobalamin C (N = 48) disease were included. Median (range) duration of treatment with betaine anhydrous was 6.8 (0-9.8) years. The prescribed betaine dose exceeded the recommended maximum (6 g/day) in 49% of individuals older than 10 years because of continued dose adaptation to weight; however, with disease-specific differences (minimum: 31% in B-6 nonresponsive CBS deficiency, maximum: 67% in MTHFR deficiency). Despite dose escalation no new or potential risk was identified. Combined disease-specific treatment decreased mean +/- SD total plasma homocysteine concentrations from 203 +/- 116 to 81 +/- 51 mu mol/L (p < 0.0001), except in MTHFR deficiency. Recommendations for betaine anhydrous dosage were revised for individuals >= 10 years. PPPs between MAH and international scientific consortia can be considered a reliable model for implementing a PASS, reutilizing well-established structures and avoiding data duplication and fragmentation.

Filiaciones:
Mütze U:
 Division of Child Neurology and Metabolic Medicine, Centre for Child and Adolescent Medicine, University Hospital, Heidelberg, Germany

Gleich F:
 Division of Child Neurology and Metabolic Medicine, Centre for Child and Adolescent Medicine, University Hospital, Heidelberg, Germany

Garbade SF:
 Division of Child Neurology and Metabolic Medicine, Centre for Child and Adolescent Medicine, University Hospital, Heidelberg, Germany

Plisson C:
 Recordati Rare Diseases, Puteaux, France

Aldámiz-Echevarría L:
 Instituto de Investigación Santiago de Compostela (IDIS), Spain

Arrieta F:
 Endocrinology & Nutrition, Metabolic Congenital Disease, H.U. Ramon y Cajal, Madrid, Spain

Ballhausen D:
 Pediatric Unit for Metabolic Diseases, Woman-Mother-Child Department, Lausanne University Hospital, Lausanne, Switzerland

Zielonka M:
 Division of Child Neurology and Metabolic Medicine, Centre for Child and Adolescent Medicine, University Hospital, Heidelberg, Germany

Ramadža DP:
 Department of Pediatrics, University Hospital Centre Zagreb and University of Zagreb, School of Medicine, Zagreb, Croatia

Baumgartner MR:
 Division of Metabolism and Children's Research Center, University Children's Hospital, University of Zurich, Zurich, Switzerland

Cano A:
 Centre de Référence des Maladies Héréditaires du Métabolisme, CHU La Timone Enfants, Marseille, France

Jiménez MCG:
 Metabolic Department, University Children Miguel Servet Hospital, IIS, Aragon, Spain

Dionisi-Vici C:
 Division of Metabolism, Bambino Gesù Children's Hospital IRCCS, Rome, Italy

Ješina P:
 Department of Pediatrics and Inherited Metabolic Disorders, Charles University-First Faculty of Medicine and General University Hospital, Prague, Czech Republic

Blom HJ:
 Department of Clinical Genetics, Center for Lysosomal and Metabolic Diseases, Erasmus Medical Center, Rotterdam, Netherlands

Couce ML:
 Unit of Diagnosis and Treatment of Congenital Metabolic Diseases, Service of Neonatology, Department of Pediatrics, Hospital Clínico Universitario de Santiago, CIBERER, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain

Meavilla-Olivas SM:
 Pediatrics, Gastroenterology, Hepatology and Nutrition, Hospital Sant Joan de Déu, Barcelona, Spain

Mention K:
 Centre de Référence des Maladies Héréditaires du Métabolisme, Hôpital Jeanne de Flandre, Lille, France

Mochel F:
 AP.HP, Sorbonne University, Reference Center for Adult Neurometabolic Diseases, La Pitié-Salpêtrière University Hospital, Paris, France

Morris AAM:
 Alder Hey Children's NHS Foundation Trust, Liverpool, UK

 Manchester Centre for Genomic Medicine, Manchester University Hospitals NHS Trust, Manchester, UK

Mundy H:
 Evelina London Children's Hospital, London, UK

Redonnet-Vernhet I:
 Endocrinology, Nutrition and Metabolic Diseases, Haut-Lévêque Hospital, Bordeaux University, Bordeaux, France

Santra S:
 Department of Clinical Inherited Metabolic Disorders, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK

Schiff M:
 Necker Hospital, APHP, Reference Center for Inborn Error of Metabolism and Filière G2M, Pediatrics Department, University of Paris, Paris, France

 Inserm UMR_S1163, Institut Imagine, Paris, France

Servais A:
 Nephrology and Transplantation, MAMEA Reference Center, Necker hospital, APHP, Paris, France

Vitoria I:
 Unit of Metabolic Disorders, Universitary Hospital La Fe, Valencia, Spain

Huemer M:
 Division of Metabolism and Children's Research Center, University Children's Hospital, University of Zurich, Zurich, Switzerland

 Department of Pediatrics, Landeskrankenhaus Bregenz, Bregenz, Austria

Kožich V:
 Department of Pediatrics and Inherited Metabolic Disorders, Charles University-First Faculty of Medicine and General University Hospital, Prague, Czech Republic

Kölker S:
 Division of Child Neurology and Metabolic Medicine, Centre for Child and Adolescent Medicine, University Hospital, Heidelberg, Germany
ISSN: 01418955





JOURNAL OF INHERITED METABOLIC DISEASE
Editorial
WILEY, 111 RIVER ST, HOBOKEN 07030-5774, NJ, Países Bajos
Tipo de documento: Article
Volumen: 45 Número: 4
Páginas: 719-733
WOS Id: 000778668900001
ID de PubMed: 35358327
imagen Green Submitted, Green Published, hybrid

MÉTRICAS